Introduction
Over 14 million colonoscopies are performed in the United States every year and as many as 50% of patients use over-the-counter bowel purgatives. 1 One such popular purgative is polyethylene glycol 3350 combined with sports drink (PEG-SD), often used in conjunction with bisacodyl. PEG-SD is hypoosmotic, containing substantially less sodium, potassium, and chloride compared to polyethylene glycol-electrolyte (PEG-ELS) formulations available by prescription. [2] [3] [4] [5] [6] PEG-ELS is nearly isosmotic to minimize electrolyte shifts and replace those lost during purgation.
Published studies have evaluated the efficacy of PEG-SD, but little data exists regarding its safety or risk of electrolyte abnormalities. In particular, a hypoosmotic purgative in patients following a clear liquid diet may increase the risk for hyponatremia. Hypoosmolar hyponatremia may occur with excessive ingestion of electrolyte-free water -typically due to water retention by the kidneys in response to antidiuretic hormone (ADH). ADH is released in the setting of intravascular volume depletion, such as with bowel purgation. Hyponatremia also occurs in euvolemic patients, most commonly due to the syndrome of inappropriate ADH (SIADH).
SIADH is associated with many factors including nausea, anxiety, pain, trauma, tumors, and certain medications. 7 Many of these factors, and dehydration, are seen in patients coming for colonoscopy. Severe hyponatremia may result in seizures, arrhythmias, coma, and death.
The incidence of hyponatremia associated with polyethylene based purgatives is difficult to estimate since neither pre-nor post-colonoscopy chemistries are routinely performed.
Hyponatremia does occur with PEG-ELS. In a prospective study of 40 patients undergoing colonoscopy after 2-3L PEG-ELS, the incidence of hyponatremia was 7.5%. 8 Ayus et al.
described two patients with severe hyponatremia after consuming 4L PEG-ELS, one of whom developed seizures (Na = 116 mmol/L) and the other died from cardiac arrest (Na = 122 mmol/L). 9 A larger prospective trial comparing 2L to 4L PEG-ELS demonstrated a 5-6%
incidence of new-onset peri-procedure hyponatremia in both groups. 10 Hyponatremia has also been reported with PEG-SD. A case report described new onset seizure after taking PEG-SD. 11 In a case series reported only in abstract, nine patients who underwent outpatient colonoscopy developed hyponatremia. 12 Eight were hospitalized and two of those had serious sequelae. Finally, in a recent study comparing the efficacy of multiple regimens of PEG-ELS and PEG-SD that was not powered for the outcome of hyponatremia, no instances of hyponatremia were observed. 13 The primary objective of this study was to evaluate whether the incidence of hyponatremia is greater with PEG-SD compared to PEG-ELS. We hypothesized that compared to PEG-SD, hyponatremia would occur significantly less often with PEG-ELS.
Materials and Methods

Participants
This was a prospective, randomized, investigator blind study at a single academic center, Diet was standardized and identical for both groups with a low residue breakfast before 10 am the day prior, followed by clear liquids up to 2.5 hours before colonoscopy. In addition to the purgative requirements, patients were instructed to consume at least an additional 4L of clears. A research physician uninvolved in the colonoscopy was available to patients by phone at any time.
Immediately prior to colonoscopy, patients completed questionnaires evaluating compliance, tolerance, fluid ingestion, and anxiety. Compliance was assessed by whether <90% or >90% of each purgative dose was ingested. Tolerance was measured using a 10-point Likert scale which rated nausea, vomiting, abdominal pain, lightheadedness, and bloating from 0 (none) to 10 (severe). In addition to the 2L purgative, patients estimated fluid intake the day prior to colonoscopy as <3L, 3-5L, or >5L (see "Patient Questionnaire" Addendum). Anxiety was scored using the Beck Anxiety Inventory© (BAI), consisting of 21 items rated on a scale of 0 (none) to 3 (severe) and added into a final score: minimal (0-7), mild (8) (9) (10) (11) (12) (13) (14) (15) , moderate (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , and severe (26-63). 22 Subjects' weights and vital signs, including orthostatic assessments, were measured.
Prior to placement of an intravenous (IV) line, blood was drawn ("Pre"). Patients received 1L of Plasma-lyte (Plasma-lyte®, Baxter International Inc., Deerfield, IL), (each 100 mL contains 526mg Sodium Chloride, 502mg Sodium Gluconate, 368mg Sodium Acetate Trihydrate, 37mg
of Potassium Chloride, and 30mg of Magnesium Chloride) in the peri-procedure period.
During the procedure, an investigator documented extent of exam, adverse events and interventions. After the procedure, the endoscopist graded the preparation using the Aronchick Scale for the whole colon and right colon, with excellent or good considered adequate and fair or poor considered inadequate. 23 Patients received monitored anesthesia care with propofol-based sedation administered by a certified registered nurse anesthetist. Following the colonoscopy and 1L of Plasma-lyte, blood ("Post") was again collected. An investigator uninvolved in the colonoscopy reviewed the final pathology report and this was used to record polyp size and histology.
Patients were asked not to discuss their preparation with the endoscopist at any time. All instructions and assessments were done privately without the endoscopist present. At the time of colonoscopy, the endoscopist documented whether s/he remained blind to the preparation. All colonoscopies were performed by attending gastroenterologists without fellow participation.
Outcome Measures
The primary outcome was the development of hyponatremia on the day of colonoscopy (serum sodium <135 mmol/L at pre-or post-colonoscopy assessment). Secondary endpoints included the change from baseline for serum electrolytes (sodium, potassium, chloride, calcium corrected for albumin), renal function, serum osmolality, and vasopressin. Additional secondary outcomes included the development of abnormal serum electrolyte values, development of orthostatic hypotension, side effects, compliance with preparation completion, and colonoscopy quality (preparation, completion, adenoma detection). Changes in levels of electrolytes and renal function were computed as the difference between the lowest value on the day of colonoscopy (pre-or post-procedure) and the baseline assessment. Changes in creatinine, BUN, osmolality, and vasopressin were computed as the difference between the highest value on the day of colonoscopy and the baseline assessment. Using a 2-sided chi-squared test with alpha 0.05 and a target sample size of 185 patients per arm, the study was designed to have at least 80% power to detect a threefold difference (odds ratio of 0.33) between PEG-ELS and PEG-SD with respect to the incidence of hyponatremia (5% vs. 14%).
Statistical Analysis
Exact methods (exact confidence interval and Fisher's exact test) were used to compare the two groups (PEG-ELS vs. PEG-SD) on incidence of hyponatremia and other electrolyte abnormalities, preparation completion and quality, incidence of side effects, and colonoscopy findings. Student's t-test was used to compare the two groups on the change in serum measures between baseline and day of colonoscopy, and the Kruskal-Wallis test was used to compare the two groups on the preparation's side effects and anxiety scores. All analyses followed the intentto-treat principle, but ineligible patients or those who withdrew after randomization were excluded from all analyses. In addition, patients who did not have blood work were excluded from the electrolyte analyses. All analyses were conducted in SAS 9.3 (SAS Institute Inc., Cary, NC) and StatXact 9 (Cytel Software Corp., Cambridge, MA). All authors had access to the final study data and approved the manuscript for publication.
Results
From June 2010 through June 2012, 638 patients were assessed for eligibility and 389
were randomized to PEG-ELS or PEG-SD (figure 1). Twenty-five patients were excluded, including 16 patients for abnormal baseline laboratories (13 with hyponatremia, range 130-134 mmol/L). The analyses included 364 patients, 180 in the PEG-SD group and 184 in the PEG-ELS group. The study colonoscopies were performed by nine physicians, although >75% were performed by two endoscopists. Endoscopist masking was preserved for 175 patients in each group (p=0.415). Table 1 summarizes study patient characteristics. Compared to the PEG-SD group, the PEG-ELS group included more females and Blacks.
Phlebotomy was completed pre-procedure for all patients except one in the PEG-SD group, and post-procedure for 175 (97%) in the PEG-SD group and 180 (98%) in the PEG-ELS group. Hyponatremia was observed in 11 patients, 7 (3.9%) in the PEG-SD group and 4 (2.2%)
in the PEG-ELS group (odds ratio, OR=1.82, exact 95% confidence interval, CI: 0.45 to 8.62, p=0.376). For these 11 patients, the mean change in sodium was -5.3, SD=2.7, with no instances of Na <131 mmol/L. Table 2 compares the 11 patients who developed hyponatremia in both groups with the 353 patients who did not. Nine of the 11 patients (82%) who developed hyponatremia were taking a diuretic (thiazide, loop, or potassium-sparing) at the time of colonoscopy, compared to 52 of the 353 (15%) of patients without hyponatremia (p=0.001).
Anxiety scores were similarly low in patients who developed hyponatremia and those who did not (mean = 3.0 vs. 3.8, respectively). Table 3 summarizes the incidence of serum electrolytes outside the normal range at both baseline and day of colonoscopy. For all electrolytes, serum levels outside the normal range on the day of colonoscopy were not significantly greater in the PEG-SD group. Four patients had an elevated creatinine (>1.4 mg/dL) on the day of colonoscopy, 3 (0.7%) in the PEG-SD group and 1 (0.5%) in the PEG-ELS group (p=0.368, range 1.5-1.7 mg/dL). In 2 of these PEG-SD patients, the creatinine elevation was new. Table 4 summarizes the serum levels of electrolytes at baseline and day of colonoscopy.
Sodium levels decreased by an average of 0.7 mmol/L in the PEG-SD group and increased by an average of 0.5 mmol/L in the PEG-ELS group (p=0.001). The decrease from baseline was also small but statistically greater for potassium and chloride in the PEG-SD group. Although hypokalemia was somewhat more common in the PEG-ELS group, the degree of hypokalemia was greater among those in the PEG-SD group. For calcium, creatinine, or osmolality, the two groups were not significantly different.
Orthostatic hypotension was rare and not statistically different between the two groups (p=0.677). At baseline, there were 3 cases of orthostatic hypotension in the PEG-SD group and 8
in the PEG-ELS group. On the day of colonoscopy, there were 6 and 8 patients, respectively, and in no case did hypotension occur in the same patient at both time points. No patients with orthostatic hypotension were symptomatic. There was no significant difference between study groups in change in vital signs from baseline to colonoscopy.
Purgative completion, fluid intake, side effects and colonoscopy findings are summarized in Table 5 . Completion of >90% of both purgative doses was high for all study patients -98%
for PEG-SD and 95% for PEG-ELS. Most patients consumed 3-5 liters of fluids the day before colonoscopy. Overall fluid consumption was greater in the PEG-SD group (p=0.007). Neither incidence nor severity of any side effect differed significantly between the two groups (p=0.124), although more patients receiving PEG-SD experienced nausea (p=0.061). Levels of anxiety were low and similar between the two study groups (p=0.162). Minimal anxiety was reported by 86%
of the PEG-SD group vs. 84% of the PEG-ELS patients.
The average number of polyps per patient was 1.0 in both groups (p=0.962). In the PEG-SD group, 118 adenomas were detected in 179 patients (0.66 adenomas/patient), and 57 patients had at least one adenoma (32%). In the PEG-ELS group, 125 adenomas were detected in 183 patients (0.68 adenomas/patient), and 59 patients had at least one adenoma (32%). The two groups did not differ on the histology of the 356 polyps (p=0.982), having similar fractions of tubular adenomas (59% in PEG-SD, 56% in PEG-ELS), sessile serrated adenomas (8% in both groups), traditional serrated adenomas (3% in both groups), and hyperplastic polyps (30% and 33%, respectively).
Two serious adverse events occurred during the study. After taking the preparation but before colonoscopy, one patient in the PEG-SD group had an acute myocardial infarction requiring cardiac catheterization and subsequent coronary bypass surgery. One patient in the PEG-ELS group had an asthma attack after taking 1L of the preparation and did not undergo colonoscopy. Figure 2 illustrates preparation quality. A similar fraction of patients in the two study groups had adequate preparations (whole colon: 87% PEG-SD, 86% PEG-ELS, p=0.878; right colon: 85% PEG-SD, 88% PEG-ELS, p=0.539). However, the PEG-ELS group had a greater proportion of excellent preparations (whole colon: PEG-SD, 57% good, 30% excellent; PEG-ELS, 34% good, 52% excellent; p=0.001).
Discussion
PEG-SD is commonly prescribed for bowel preparation. No clinical trials have
previously evaluated safety endpoints, such as electrolyte and volume changes after administration, as a primary outcome. A randomized study powered for efficacy, but not safety, compared split dosing to day prior dosing of PEG-SD in 114 patients. 13 Serum chemistries drawn immediately prior to colonoscopy showed no cases of hyponatremia. Nevertheless, case reports of patients taking PEG-ELS or PEG-SD indicate that severe hyponatremia does occur. 8-9,11-12 The reported incidence rates of any degree of hyponatremia following PEG-ELS may be as high as 8%. [9] [10] Because PEG-SD is markedly more hypo-osmotic than PEG-ELS, the purpose of this study was to determine whether PEG-SD confers a greater risk for hyponatremia.
This large, prospective, randomized study showed that hyponatremia occurs very infrequently following ingestion of either PEG-ELS or PEG-SD. There was no significant difference in the incidence of hyponatremia between these purgatives. However, the observed incidence of hyponatremia with both purgatives was low and less than predicted. Using the observed incidence, a study four times larger would be needed to prove hyponatremia occurs significantly less often with PEG-ELS than with PEG-SD using the pre-set margins.
Furthermore, when hyponatremia occurred, the degree was minor (range 131-134 mmol/L) and asymptomatic. The incidence of hypokalemia, hypochloremia, and hypocalcemia was also uncommon and did not significantly differ between the two study groups. A total of 13 patients (6 PEG-SD, 7 PEG-ELS) had some degree of hemolysis on their day of colonoscopy labs and were excluded from the potassium analyses; some of these patients could have been hypokalemic as well. One patient in the PEG-SD group who had hyponatremia both pre-and postcolonoscopy had mild hemolysis on post-colonoscopy blood draw.
Among study patients, there was a significantly greater decrease in serum sodium in the PEG-SD group, although this reduction was very modest. Similarly, small but significantly greater reductions in serum potassium and calcium were also observed in the PEG-SD group.
Differences in medication use and medical conditions were observed between patients who developed hyponatremia and those who did not. Among study patients developing hyponatremia, diuretic use was significantly greater and the use of an ACEI or ARB more common. Significantly more patients who developed hyponatremia had diabetes, and a greater proportion had hypertension, cardiovascular disease, or liver disease. Similar characteristics were observed among the 13 patients excluded from this study for hyponatremia at baseline screening -diuretic use in 6, ACEI or ARB use in 3, cardiovascular disease in 8, diabetes in 4, and liver disease in 4.
Adverse events, compliance, and colonoscopy quality measures were similar in patients receiving PEG-ELS and PEG-SD. The two groups were similar at baseline and on the day of colonoscopy with respect to vital signs, changes in vital signs, and the incidence of orthostatic hypotension. No patients exhibited symptoms or signs of volume depletion. The incidence of adverse events was not significantly different between the two groups, and nearly all patients in both groups completed both doses of purgative. Finally, similar rates of adenoma detection and colonoscopy completion were observed between the study groups.
Bowel cleansing was evaluated as a secondary endpoint. Overall, the quality of bowel preparation was similar between the two groups, with no difference in the number of patients with adequate or inadequate preparations. However, focusing on adequate preparations, which were categorized as excellent or good, excellent bowel preparations were observed in significantly more patients in the PEG-ELS group.
There are several strengths to our study. Prior studies evaluating PEG-SD have had cleansing efficacy as the primary endpoint, including a publication reporting on the incidence of hyponatremia but not powered to evaluate this outcome. 13 Our randomized controlled trial was designed specifically to evaluate safety measures, with the primary endpoint the incidence of hyponatremia. Other serum electrolytes, renal function, and volume status were also studied. All study patients followed a split dosing schedule, and both groups were consistent with respect to the timing of purgative ingestion (pre-colonoscopy) and completion of peri-procedure fluids (post-colonoscopy).
The population studied is fairly representative of outpatients reporting for colonoscopy with respect to age, gender, indications and medical history. The procedure for anesthesia was also standardized. We controlled for anxiety, as this is an independent factor associated with hyponatremia via activation of the hypothalamus-pituitary-adrenal (HPA) axis and increased levels of vasopressin. 24, 25 Furthermore, the volume of fluids ingested the day prior was also considered in the analysis, as ingestion of free water increases the risk for hyponatremia.
There are several limitations to our study. First, although our primary study endpoint was serum sodium < 135 mmol/L, serious adverse events related to hyponatremia such as seizure, coma, arrhythmias, and even death are usually associated with serum sodium < 130 mmol/L.
This study was not designed to detect the incidence of severe hyponatremia. A much larger study with thousands of patients would be needed to assess the incidence of severe hyponatremia is significantly different between PEG-SD and PEG-ELS. Second, the much lower use of diuretics in the PEG-SD group may have had a mitigating effect on the incidence of hyponatremia in these patients as compared to the PEG-ELS group. Unfortunately, because of the small number of hyponatremia cases, multivariable analyses that would have adjusted for baseline differences were not possible. Third, few patients were actually enrolled with medical conditions placing them at higher risk for hyponatremia, such as those with chronic liver or kidney disease. Heart failure was classified within the category of cardiovascular disease. It is worthwhile noting that vulnerable patient populations such as those with cirrhosis, heart failure, and renal disease are standardly excluded from clinical purgative trials performed for the purpose of gaining FDA approval. 10, [14] [15] [16] [17] Unlike routine clinical practice, baseline serum electrolytes were required for this study, and those found to be hyponatremic were excluded. These patients did not have a history of hyponatremia and, in all likelihood, would have undergone colonoscopy in a non-study setting.
The follow up of these patients is not available as they were discharged to the care of their primary gastroenterologist. The inclusion of such patients may have increased the incidence of hyponatremia for both study groups.
In conclusion, this study shows that hyponatremia is a rare event after ingestion of either PEG-ELS or PEG-SD for colonoscopy. Patients using diuretics may be more likely to develop hyponatremia in the setting of purgative ingestion for colonoscopy. While the risk associated with specific medications or medical disorders deserves further investigation, PEG-SD is a reasonable option for patients without a history of hyponatremia or medical conditions conferring a high risk. Although this study does not prove the safety of PEG-SD for use as a bowel purgative, it suggests that in patients at low risk for hyponatremia, the risk for hyponatremia with either PEG-SD or PEG-ELS for colonoscopy is small.
ACKNOWLEDGMENTS
We wish to thank Angela Gordon, RN for her assistance with patient visits and procedures and laboratory and data collection. We also thank Irene Dialino for her assistance with data collection during procedures, and subject chart organization and management. Finally, we acknowledge Cynthia Miller, RN for research assistance and creating the study database. (13) 1 (1) 37 (20) 11 (6) 25 (14) 6 ( Fluid intake before procedure (L),* n (%) < 3L 3-5L > 5L
24 (13) 145 (81) 10 (6) 43 (24) The primary outcome for preparation quality was adequate (excellent or good) vs. inadequate (fair or poor). Excellent for whole colon: PEG-SD=30% vs. PEG-ELS=52%. Good for whole colon: PEG-SD=57% vs. PEG-ELS 34%, p=0.001.
